Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)
Completed · Phase 2
Conditions studied: Familial Partial Lipodystrophy
In brief
This is a single-center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of fasting triglycerides in participants with familial partial lipodystrophy.
Key facts
- Study ID
- NCT03514420
- Run by
- Akcea Therapeutics
- People needed
- 4
- Starts
- 2018-06-15
- Expected to finish
- 2019-08-21
- Last updated by the study team
- 2021-02-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Clinical Site — Ann Arbor, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.